生物資訊：2006年至2011年的市場預測

Abstract

"Outsourcing defines future of Euro Bioinformatics market" "Jump on bioinformatics bandwagon"

These are just two newspaper headlines that appeared today. Managing your data is critical to your organisation. You already know that. But is your company doing it as effectively as it should? Find out by reading this brand new report.

This report delivers answers on how you can benefit from the commercial prospects of bioinformatics, now. The ultimate goal of bioinformatics is to uncover the wealth of biological information hidden in the mass of data, to obtain a clearer insight into the fundamental biology of organisms. Is your Bioinformatic strategy working to the maximum level. These recent developments have a profound relevance to pharmaceutical development.

These technological solutions are now a vital part of pharmaceutical R&D, enabling researchers to store, interpret and apply increasing volumes of data. We forecast that bioinformatics will exhibit steady growth in revenues from 2006-2011, with significant investments being made by companies in the pharmaceutical sector. Key technological challenges - such as harnessing information from The Human Genome Project - will drive that expansion. Are you directing your investments in the right way? Is your data working for you effectively? This report will tell you.

This in-depth report for senior management examines pharmaceutical applications of bioinformatics critically, through in-depth primary and secondary research, Interviews with the industry's leading strategists, questionnaires and industry polls. Plus through continuous consultation with experts in industry and academia, this research involved a detailed study of policy documents, industrial reports and relevant news. We have also applied techniques such as financial forecasting, SWOT analyses and qualitative projections, as well as our in-house GO forecasting tool. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, this report concentrates on the following essential aspects of bioinformatic solutions in the pharmaceutical sector:

• Innovative technologies that drive the bioinformatics industry
• Key industrial players in bioinformatics - including partnerships in this field
• Forecasts of the bioinformatics market from 2006-2011, including forecasts of principal market segments and geographical regions
• Drivers and opportunities for you in the bioinformatics sector
• Restraints and threats in the bioinformatics sector and how to avoid them
• Assessments of relevant business models, technological solutions and associated issues
• Coverage of academic developments and future trends in the sector - possible partnerships?
• Interviews with key figures and wide ranging insight from leading experts

Why you must buy this report today:

• To receive a comprehensive analysis of the prospects for bioinformatic solutions in the pharmaceutical sector from 2006-2011
• To discover predicted revenues, growth rates and other key metrics for bioinformatic solutions from 2006-2011
• To receive the views of experts on bioinformatics in both industry and academia
• To determine the forces that influence the market for bioinformatics with pharmaceutical applications:
• Competitive characteristics of the market
• Drivers
• Restraints
• Strengths, weaknesses, opportunities and threats
• To find out where bioinformatics is heading - both technologically and commercially

Unique benefits

• Full searchable report when you buy the company or corporate editions
• Immediate access through our exclusive Reading Room
• You can access your report whichever country you are in without using hard drive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables
• Full after purchase care and analyst assistance

Table of Contents

1. Executive Summary: Bioinformatics 2006-2011

2.Introduction - Bioinformatics is A Key Enabling Technology in Drug Development

• 2.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
• 2.2 The Continuing Success of the Pharmaceutical Industry is Dependent Upon Important Drivers and Restraints
• 2.3 The Pharmaceutical Sector Is Gradually Changing Its Strategic Focus to Overcome Challenges in the Market
  • 2.3.1 Reducing Efficiencies in R&D Result in Concerns Over Thinning Pipelines
• 2.4 The Growing Market for Bioinformatic Products and Services: Where Information Technology Combines with Science & Research
  • 2.4.1 Bioinformatics Is Highly Relevant to Pharmaceutical Development
• 2.5 Bioinformatics Developed As a Consequence of Increasing Requirements for Computational Resources in the Life Sciences
  • 2.5.1 Computational Biology
  • 2.5.2 The Human Genome Project Has Provided Important Scope for the Development and Use of Bioinformatics
  • 2.5.3 Pharmacogenomics is Increasingly Relevant to Pharmaceutical Development
  • 2.5.4 Proteomics Constitutes the "Next Step" After Genomics
• 2.6 Biological Databases
• 2.7 Bioinformatic Tools for Searching and Analysis
  • 2.7.1 Sequence Analysis
  • 2.7.2 Genomic Annotation
  • 2.7.3 Similarity Searching
  • 2.7.4 Analysis of Gene Expression
  • 2.7.5 Analysis of Gene Regulation
  • 2.7.6 Analysis of Mutations in Cancer
  • 2.7.7 Analysis of Protein Expression
  • 2.7.8 Structural Analysis of Proteins
  • 2.7.9 Functional Analysis of Proteins
• 2.8 Other Applications of Bioinformatics with Relevance to Medicine
  • 2.8.1 High-Throughput Image Analysis and Morphometrics
  • 2.8.2 Modelling Biological Systems "In Silico"
• 2.9 Potential Benefits of Using Bioinformatic Tools in the Pharmaceutical Industry

3. Forecast of the Market for Bioinformatics, 2006-2011

• 3.1 Spending on Bioinformatics Will Increase Strongly from 2006-2011
  • 3.1.1 The Race to Make Use of The Human Genome Has Already Started, Resulting In a Large Boost for The Sales of Bioinformatic Products and Services In the Pharmaceutical Sector
  • 3.1.2 Bioinformatics Is An Emerging But Fragmented Industry
  • 3.1.3 New Technologies Lead to An Increasing Demand for Bioinformatic Solutions
  • 3.1.4 To Be Truly Successful, Bioinformatic Technology Providers Need to Understand the Value Chain in Drug Development
• 3.2 The US will Continue to Lead the World in Spending on Bioinformatics
• 3.3 Analytical Software Will Contribute the Highest Proportion of Revenues in the Global Bioinformatics Market
  • 3.3.1 Emerging Bioinformatic Technologies Can Reduce The Time and Costs of Developing Drugs Significantly, But Greater Validation of the Technology is Required
  • 3.3.2 Databases and Related Content Remain An Important Part of the Bioinformatics Market
  • 3.3.3 High-Throughput Screening is Another Key R&D Technology that Serves As a Driver for Sales of Bioinformatic Tools for Data Storage and Analysis
• 3.4 The Share of Bioinformatics Revenues Contributed by Proteomic Applications Will Increase At the Expense of Genomic Applications
  • 3.4.1 Genomics and Proteomics are Closely Linked, With The Profile of the Latter Rising
  • 3.4.2 There is a Need For More Unified, Holistic Solutions in Bioinformatics
  • 3.4.3 Pharmacogenomics Can Potentially Change The Paradigm of Drug Development
  • 3.4.4 The Successful Application of Pharmacogenomics Will Require Regulatory Changes - Some Progress is Evident, But Much Uncertainty Remains
• 3.5 Conclusions from Visiongain's Forecast for the Pharmaceutical Bioinformatics Market

4. A Discussion of Issues Affecting Bioinformatics in Pharmaceutical Applications

• 4.1 A SWOT Analysis for the Bioinformatics Sector With Relevance to Pharmaceutical Development
• 4.2 Bioinformatic Solutions Will Continue To Expand Their Presence in the Pharmaceutical Industry - Further R&D Efficie ncies Are Predicted
• 4.3 Bioinformatic Applications Face No Significant Restraints to Their Continuing Adoption Within the Pharmaceutical Sector
• 4.4 Vast Amounts of Data Remain to Be Processed via Bioinformatics - There is a Need For Holistic Solutions In Particular
• 4.5 Bioinformatics Is Presently A Complex Mix of Public and Private Data Sources
• 4.6 Trends in the Market for Bioinformatic Products and Services with Pharmaceutical Relevance
• 4.7 Bioinformatics Is One of The Most Important Areas of Investment Among The Emerging Technologies
• 4.8 Benefits of Informatics in Drug Discovery & Development Are Real
• 4.9 Developments in Genomics Drive the Bioinformatics Market, With Benefits to the Pharmaceutical Industry Increasing from 2006-2011
• 4.10 Bioinformatics Companies Have To Change Their Commercial Focus If They Are to Succeed
  • 4.10.1 Some Bioinformatics Companies Have Struggled In Recent Years
  • 4.10.2 Leaders In Mainstream IT Provide Extra Competition for Specialised Bioinformatics Companies
  • 4.10.3 Some Drug Discovery Companies Are Moving Into Bioinformatics
• 4.11 There is Still A Perception That Bioinformatic Solutions Are Restricted to Highly Specialised Applications
• 4.12 Recent Trends in the Business Strategies Adopted by Informatic Companies
  • 4.12.1 The Decision to Adapt to Changing Market Demands
  • 4.12.2 Informatics Companies to Span Life Science Market Areas
  • 4.12.3 Changing the Focus from Informatics Services to Tackling Therapeutic Drug R&D Bottlenecks & Content
  • 4.12.4 Expanding Services to Incorporate Drug R&D Processes
• 4.13 The Commercialisation of Informatics in the Pharmaceutical & Biotechnology Industry
  • 4.13.1 Recent Trend from In Vivo Research to In Silico Research
  • 4.13.2 A Shift in Commercial Focus for the Application of Informatics
  • 4.13.3 The Use of Informatics to Transform Genomic Sequence Data into Drug Targets

5. Current Events in Bioinformatics That Are Indicative of the Prevailing Direction of The Sector

• 5.1 Fundamental Issues Affecting the Current Market
  • 5.1.1 Broadening Business Strategy to Span other Life Science Areas
  • 5.1.2 There is Intense Competition in the Bioinformatics Market
  • 5.1.3 Lion Bioscience Sold Its Loss-Making Bioinformatics Unit
• 5.2 The Current Success of the Biotechnological Industry Will Greatly Benefit the Bioinformatics Sector
• 5.3 Broadening Business Strategy to Span other Life Science Areas
• 5.4 Partnerships in the Bioinformatics Sector
  • 5.4.1 There is an Increasing Trend to Outsource, With India Being a Beneficiary
  • 5.4.2 Bioinformatics Partnership Announced by IDBS and In Silico Discovery
  • 5.4.3 Invitrogen Forms Collaboration with Solexa
  • 5.4.4 Sigma-Aldrich Launches Online Tool for Analysing Biological Pathways
  • 5.4.5 Novascreen Launches a Screening Service for Next-Generation Drug Screening
  • 5.4.6 AstraZeneca Is Placing A Great Emphasis on Imaging Technology to Benefit Development
  • 5.4.7 Sigma-Aldrich and Rosetta Inpharmatics Establish Partnership for siRNA Design
  • 5.4.8 Collaboration Between GenoLogics Life Sciences Software and Bioinformatics Solutions Could Provide Important Gains in Proteomics Research
  • 5.4.9 Capgemini wins IT Contract With Eli Lilly
  • 5.4.10 Pfizer harnesses Indian IT and Bioinformatics Strengths
• 5.5 CuraGen Show Marked Innovation In Bioinformatics, Especially the Combining of Functions
• 5.6 Current Developments Will Have A Strong Positive Effect on Bioinformatics, With Benefits to Pharmaceutical R&D

6. Future Developments in Bioinformatics

• 6.1 Responses to Question Submitted to Experts in Industry and Academia Concerning Future Trends in Bioinformatics
  • 6.1.1 Views on the Current State of the Bioinformatics Market
  • 6.1.2 The Issues Needed to be Considered By Pharmaceutical Companies With Regard to Bioinformatics
  • 6.1.3 Will Bioinformatics Significantly Increase Efficiencies in R&D?
  • 6.1.4 What Are The Most Promising Applications in Pharmaceutical R&D?
  • 6.1.5 Will Bioinformatics Become Increasingly Prominent in R&D?
  • 6.1.6 Is Bioinformatics Truly Moving from Gene Discovery to Proteomics?
  • 6.1.7 Will Bioinformatics Impact Upon Clinical Testing?
  • 6.1.8 Will the Validation of Bioinformatic Tools Become Standard Practice?
  • 6.1.9 The Role of Bioinformatics Companies
• 6.2 Academic Institutions Play An Important Role In Developmental Aspects of Bioinformatics
  • 6.2.1 Leading Bioinformatics Groups Worldwide
  • 6.2.2 Wellcome Trust Sanger Institute, UK
  • 6.2.3 The Brutlag Bioinformatics Group - Stanford University, US
  • 6.2.4 The University of Manchester Bioinformatics Group, UK
  • 6.2.5 The European Bioinformatics Institute (EBI), UK
  • 6.2.6 South African National Bioinformatics Institute (SANBI)

7. Conclusions

• 7.1 Bioinformatics and its Applications in the Pharmaceutical Industry
• 7.2 Visiongain Predicts Strong Growth in Revenues for Bioinformatic Services and Products
• 7.3 Analytical Software Will Contribute the Highest Proportion of Revenues in the Global Bioinformatics Market
• 7.4 The Bioinformatics Sector Will Benefit From Strong Driving Forces - Especially The Race To Apply Genomic Data
• 7.5 There Are Some Restraints to the Bioinformatics Sector But These Will Not Have a Particularly Drastic Effect
• 7.6 The Situation for Pharmaceutical Bioinformatics Is Very Positive Overall

Appendices

• Appendix A. Transcripts of Interviews with Key Industry Experts
• Appendix A.1 Interview with Dr Edward Maggio, Chairman & CEO, Structural Bioinformatics
• Appendix A.2 Interview with Dr David Speechly, Vice President of Investor Relations, Applied Biosystems
• Appendix A.3 Interview with Dr George J. Maalouf, President, Genomix Corporation
• Appendix B. About visiongain

List of Tables

• Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
• Table 2.2 Informatic Market Segments Relevant to the Pharmaceutical Industry
• Table 3.1 Total World Spending ($bn) on Bioinformatics, 2005-2011
• Table 3.2 Total World Spending ($bn) on Drug Discovery, 2005-2011
• Table 3.3 Spending on Bioinformatics As a Percentage (%) of Total Spending on Drug Discovery, 2005-2011
• Table 3.4 Market Share (%) and Spending ($m) on Bioinformatics by Geographical Region, 2005 & 2011
• Table 3.5 A Breakdown of World Bioinformatics Spending ($m) According to Product/Service Type, 2005-2011
• Table 3.6 Contributions (%) to World Bioinformatics Spending According to Product/Service Type, 2005 & 2011
• Table 3.7 Contributions ($m) to World Bioinformatics Spending by Applications for Pharmacogenomics and Protoeomics, 2005-2011
• Table 3.8 Contributions (%) to World Bioinformatics Spending by Applications for Pharmacogenomics and Protoeomics, 2005-2011
• Table 4.1 A SWOT Chart for the Bioinformatic Applications in the Pharmaceutical Sector, 2006-2011
• Table 4.2 Expenditure of Leading Pharmaceutical Companies on New Technologies, 2005
• Table 4.3 Different Types of Data & Information Analysed by Informatics Techniques
• Table 7.1 Total World Spending ($bn) on Bioinformatics, 2005-2011
• Table 7.2 Spending on Bioinformatics As a Percentage (%) of Total Spending on Drug Discovery, 2005-2011
• Table 7.3 A Breakdown of World Bioinformatics Spending ($m) According to Product/Service Type, 2005-2011

List of Figures

• Figure 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
• Figure 2.2 The Increasing Average Cost ($m) of NME Development, 1976-2005
• Figure 2.3 The Role of Databases in Life Sciences Research
• Figure 2.4 Potential Applications of Informatics in Drug Discovery & Development
• Figure 3.1 Total World Spending ($bn) on Bioinformatics, 2005-2011
• Figure 3.2 Total World Spending ($bn) on Drug Discovery and Bioinformatics Compared, 2005-2011
• Figure 3.3 Spending on Bioinformatics As a Percentage (%) of Total Spending on Drug
• Figure 3.4 Total World Spending ($m) on Bioinformatics by Geographical Region, 2005 and 2011
• Figure 3.5 Total World Spending (%) on Bioinformatics by Geographical Region, 2005
• Figure 3.6 Total World Spending (%) on Bioinformatics by Geographical Region, 2011
• Figure 3.7 A Breakdown of World Bioinformatics Spending ($m) According to Product/Service Type, 2005-2011
• Figure 3.8 A Breakdown of World Bioinformatics Spending (%) According to Product/Service Type, 2005
• Figure 3.9 A Breakdown of World Bioinformatics Spending (%) According to Product/Service Type, 2011
• Figure 3.10 Contributions (%) to World Bioinformatics Spending According to Product/Service Type, 2005 & 2011
• Figure 3.11 Contributions ($m) to World Bioinformatics Spending by Applications for Pharmacogenomics and Protoeomics, 2005-2011
• Figure 3.12 Contributions (%) to World Bioinformatics Spending by Pharmacogenomics and Protoeomics, 2005 & 2011
• Figure 4.1 Expenditure of Leading Pharmaceutical Companies on New Technologies, 2005

List of Organisations

• Accelrys
• Affymetrix
• Agilent
• Applied Biosystems
• Astellas
• AstraZeneca
• AxCell BioSciences
• Beckman Coulter
• BioChem Pharma
• Biodirectory
• BioDiscovery
• Bioinformatics Solutions
• Biomax Informatics
• Bio-Rad
• Capgemini
• Celera Genomics
• Compaq
• Compugen
• Confirmant
• CuraGen
• DiaDexus
• DNAStar
• Double Twist
• DuPont
• Eli Lilly
• Entigen Corporation
• Exelixis
• Fujitsu
• GE Healthcare Bio-Sciences
• Genaissance Pharmaceuticals
• Gene Codes
• GenoLogics Life Sciences Software
• Genomica
• Genomix Corporation
• Google
• Hewlett-Packard
• Hitachi
• Hybrigenics
• IBM
• IDBS
• In Silico Discovery
• Incyte Genomics
• Informax
• Invitrogen
• Johnson & Johnson
• Kirin
• Lion Biosciences
• Media Cybernetics
• Merck & Co
• Millennium Pharmaceuticals
• Motorola
• Myriad Genetics
• NetGenics
• Novartis
• NovaScreen BioSciences
• Novo Nordisk
• OGS
• Oracle
• Pfizer
• Protein Lounge
• Roche Applied Science
• Rosetta Inpharmatics
• Sanofi-Pasteur
• Sigma-Aldrich
• Silicon Genetics
• Solexa
• Spotfire
• Structural Bioinformatics
• Structural Genomix
• Sun Microsystems
• The Boston Consulting Group
• Viaken Systems
• Wyeth
• Yamanouchi